MARKET

LTRN

LTRN

Lantern Pharma Inc
NASDAQ
1.220
+0.010
+0.83%
After Hours: 1.220 0 0.00% 19:35 09/25 EDT
OPEN
1.190
PREV CLOSE
1.210
HIGH
1.280
LOW
1.160
VOLUME
220.43K
TURNOVER
--
52 WEEK HIGH
4.703
52 WEEK LOW
1.110
MARKET CAP
15.60M
P/E (TTM)
-0.7555
1D
5D
1M
3M
1Y
5Y
1D
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
Barchart · 17h ago
Lantern Pharma Highlights Open-Medicine AI Oncology Platform
TipRanks · 2d ago
Lantern Pharma Showcases Open-Medicine AI Growth Strategy
TipRanks · 3d ago
Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12:30 PM ET
Barchart · 3d ago
Lantern Pharma secures USPTO notice of allowance for LP-284 patent
TipRanks · 4d ago
Lantern Pharma Issued Notice Of Allowance From U.S. Patent And Trademark Office For Application Titled Method For Treating Blood Cancers
Benzinga · 4d ago
Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas
Barchart · 4d ago
Weekly Report: what happened at LTRN last week (0914-0918)?
Weekly Report · 5d ago
More
About LTRN
Lantern Pharma Inc. is an artificial intelligence (AI) company. The Company is developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, leverages over 200 billion oncology-focused data points and a library of 200+ ML algorithms. It is engaged in the development of its pipeline of drug candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody drug conjugate program. Its portfolio includes a Phase II clinical program (LP-300) in NSCLC focused on never-smokers and non-smokers with the EGFR exon 21 L858R mutation; planned Phase I b/II trials (LP-184) in precision, biomarker-defined solid tumors, and an ongoing Phase II program in hematologic malignancies and adult soft tissue sarcomas (LP-284). It is also focused on the clinical execution of its therapies for CNS and brain cancers through Starlight Therapeutics Inc.

Webull offers Lantern Pharma Inc stock information, including NASDAQ: LTRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LTRN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LTRN stock methods without spending real money on the virtual paper trading platform.